Stellar, Apricus form deal for nail fungus drug in Canada
This article was originally published in Scrip
Executive Summary
While Stellar Pharmaceuticals' investors happily greeted a new licensing agreement it formed with Apricus Biosciences, the latter firm's stock got bruised.